Resources

Genoskin Expands Mast Cell AccessPress releaseGenoskin Expands Mast Cell AccessPress releaseGenoskin Expands Mast Cell AccessPress releaseGenoskin Expands Access to Primary Human Mast Cells Across North America Genoskin is pleased to announce that its primary human mast cells will now be available to customers in North America, marking a key milestone in the company's commercial development. This launch gives pharmaceutical andRead more

Conferences & eventsThank you for meeting our amazing teamGenoskin at the MPS World Summit 2026Enabling preclinical drug development with ex vivo human skin platforms Genoskin was proud to participate in the MPS World Summit 2026, held in Washington, DC, one of the leading global events dedicated to advancing microphysiological systems (MPS) and human-relevant models for drug development. The summit broughtRead more

WoundSkin® FactsheetHuman ex vivo skin model to study wound healing & bacterial infectionWoundSkin® Factsheet: Advance Your Wound Healing Research Download the WoundSkin® factsheet to explore how a physiologically relevant, wounded human skin model can support your wound healing and infection research. Built on ex vivo human skin tissue, WoundSkin® preserves the full complexity of native skin, including immune responses, whileRead more

Genoskin appoints new board memberto strengthen governancePress releaseGenoskin strengthens governance with appointment of industry leader Fabrice BouteilleA strategic milestone reinforcing independence, global growth, and leadership in human-relevant researchA new chapter in Genoskin’s growth journey Genoskin announces the appointment of Fabrice Bouteille as an independent member of its Board of Directors—marking a pivotal step in the company’s evolution following its $8.7Read more

Intradermal device testingA collaboration study with Pharma LatchReplacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM) Jérémy Argenty1, Clémence Letzelter1, Catherine Marques1, Sophie Abadie1, Alexia Sanchez1, Claire Gendrin1, Alexandra Ochando1, Adam Rock2, Ronan Byrne2, Pascal Descargues1, Nicky Bertollo2 1Genoskin, 2Pharma Latch HypoSkin® is an ex vivo human skin NAM thatRead more

Local toxicity & Formulation safetyA collaboration study with argenxHypoSkin® as a human-based NAMs platform for local toxicity and formulation safety assessment Julie Magerman1, Katarzyna Polak2, Ornella Binazon1, Michael Pastore2, Alexandra Ochando2, Judith Baumeister1 1argenx, 2Genoskin Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skin enables multi-parametric local tolerance assessment after subcutaneous injection.Read more